HOME >> BIOLOGY >> NEWS
A form of the alcohol dehydrogenase gene may protect Afro-Trinidadians from developing alcoholism

  • Alcohol dehydrogenase (ADH) is one of the major enzymes involved in alcohol metabolism.
  • New findings indicate that the ADH1B*3 allele may protect against the development of alcoholism.
  • At the same time, the ADH1B*3 allele may be a risk factor for liver disease most likely because it increases levels of acetaldehyde if an individual with the allele does drink.

Alcohol dehydrogenase (ADH) is one of the major enzymes involved in alcohol metabolism. The genes for ADH are polymorphic at two loci, ADH1B and ADH1C. While the three alleles at the ADH1B locus have previously been linked with protection from alcohol dependence, a new study is the first to examine the relationship between the ADH1B*3 allele and alcohol-related disorders among Afro-Trinidadians. Findings indicate that while the ADH1B*3 allele appears to protect against alcoholism, it can also increase the risk for liver disease among those individuals who drink heavily.

Results are published in the February issue of Alcoholism: Clinical & Experimental Research.

"Alcohol is primarily metabolized or broken down in the liver by two enzymes," explained Cindy L. Ehlers, associate professor of molecular and integrative neuroscience at The Scripps Research Institute. "The first is ADH, which converts alcohol to acetaldehyde. Acetaldehyde is a toxic compound that can be damaging to the liver and other body organ systems. The second enzyme is aldehyde dehydrogenase (ALDH), which breaks down acetaldehyde to acetate, a relatively nontoxic compound."

Ehlers said that most people do not realize that people of different racial origins metabolize alcohol differently and that this influences their risk for alcoholism. "Approximately 40 percent of Asians have a mutation in ALDH that may cause them to have an aversive reaction when they drink so they are much less likely to develop alcohol dependence
'"/>


25-Jan-2007


Page: 1 2 3 4

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Females more prone to brain damage from alcohol abuse
3. Prenatal alcohol exposure alters brain activity in the frontal-striatal areas
4. Eat fish -- especially if you drink high levels of alcohol
5. Gene variant increases risk for alcoholism following childhood abuse
6. Spouse may drive you to drink but also can protect you from alcohol
7. Hot flashes -- Studies explore the role of genes, obesity and alcohol
8. Spousal choices can influence the risk of developing alcoholism
9. Sequence variation in the alpha synuclein gene contributes to alcohol craving
10. Cholesterol could be key to treating fetal alcohol syndrome
11. New compound prevents alcoholic behavior, relapse in animals by blocking stress response

Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: